Equities Analysts Offer Predictions for BMRN Q4 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities research analysts at Zacks Research lowered their Q4 2026 EPS estimates for BioMarin Pharmaceutical in a report released on Friday, October 24th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of $1.10 per share for the quarter, down from their prior forecast of $1.13. Zacks Research has a “Hold” rating on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

Other research analysts have also recently issued research reports about the stock. Morgan Stanley cut their price objective on shares of BioMarin Pharmaceutical from $97.00 to $96.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 22nd. Guggenheim boosted their target price on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the company a “buy” rating in a research note on Wednesday, August 6th. JPMorgan Chase & Co. boosted their target price on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Wolfe Research set a $95.00 target price on shares of BioMarin Pharmaceutical and gave the company an “outperform” rating in a research note on Tuesday, July 15th. Finally, Wall Street Zen lowered shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 11th. Thirteen research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $93.26.

BioMarin Pharmaceutical Trading Down 0.1%

BMRN stock opened at $54.48 on Monday. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical has a twelve month low of $51.56 and a twelve month high of $73.51. The stock has a market capitalization of $10.46 billion, a price-to-earnings ratio of 16.17, a price-to-earnings-growth ratio of 0.68 and a beta of 0.33. The firm’s fifty day simple moving average is $55.29 and its two-hundred day simple moving average is $57.27.

Institutional Trading of BioMarin Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at about $25,000. Rise Advisors LLC bought a new stake in shares of BioMarin Pharmaceutical in the first quarter valued at about $30,000. Brooklyn Investment Group raised its holdings in shares of BioMarin Pharmaceutical by 2,250.0% in the first quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 540 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in shares of BioMarin Pharmaceutical by 480.2% in the second quarter. Hantz Financial Services Inc. now owns 1,056 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 874 shares in the last quarter. Finally, Employees Retirement System of Texas bought a new position in BioMarin Pharmaceutical in the second quarter worth about $58,000. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.